| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $2,862,802 | 10 | 100 |
| Podlesak Dennis | director | 0 | $0 | 1 | $113,716 | $-113,716 |
| Goldan Keith A. | Chief Financial Officer | 0 | $0 | 3 | $136,988 | $-136,988 |
| Botwood Nicholas A.J. | Head of R&D, CMO | 0 | $0 | 2 | $1.18M | $-1.18M |
| Metzger Michael A | Chief Executive Officer | 0 | $0 | 4 | $1.43M | $-1.43M |
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 …
Over the last 12 months, insiders at Syndax Pharmaceuticals, Inc. have bought $0 and sold $2.86M worth of Syndax Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Syndax Pharmaceuticals, Inc. have bought $133,467 and sold $9.54M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $44,950 was made by Huber Martin H. Jr. (director) on 2025‑05‑19.
| 2026-10-29 | Sale | Podlesak Dennis | director | 8,000 0.009% | $14.21 | $113,716 | -3.53% | |
| 2026-07-08 | Sale | Metzger Michael A | Chief Executive Officer | 32,375 0.0361% | $24.24 | $784,776 | -22.31% | |
| 2026-06-12 | Sale | Botwood Nicholas A.J. | Head of R&D, CMO | 31,235 0.0357% | $18.14 | $566,603 | +5.86% | |
| 2026-06-11 | Sale | Botwood Nicholas A.J. | Head of R&D, CMO | 34,280 0.0389% | $18.00 | $617,040 | +7.79% | |
| 2026-06-01 | Sale | Metzger Michael A | Chief Executive Officer | 6,847 0.0078% | $18.99 | $130,025 | +1.22% | |
| 2026-06-01 | Sale | Goldan Keith A. | Chief Financial Officer | 1,177 0.0013% | $18.99 | $22,351 | +1.22% | |
| 2026-02-09 | Sale | Metzger Michael A | Chief Executive Officer | 17,159 0.0196% | $21.03 | $360,819 | -5.14% | |
| 2026-02-09 | Sale | Goldan Keith A. | Chief Financial Officer | 3,410 0.0039% | $21.03 | $71,705 | -5.14% | |
| 2026-02-06 | Sale | Metzger Michael A | Chief Executive Officer | 7,412 0.0084% | $20.62 | $152,835 | -4.26% | |
| 2026-02-06 | Sale | Goldan Keith A. | Chief Financial Officer | 2,082 0.0024% | $20.62 | $42,931 | -4.26% | |
| 2025-09-08 | Sale | Metzger Michael A | Chief Executive Officer | 157,307 0.1836% | $16.41 | $2.58M | +24.00% | |
| 2025-08-18 | Sale | Podlesak Dennis | director | 19,200 0.0222% | $15.84 | $304,170 | +27.47% | |
| 2025-08-15 | Sale | Podlesak Dennis | director | 19,200 0.022% | $15.54 | $298,408 | +28.53% | |
| 2025-08-14 | Sale | Podlesak Dennis | director | 19,200 0.0215% | $14.19 | $272,521 | +37.34% | |
| 2025-07-16 | Sale | Metzger Michael A | Chief Executive Officer | 7,534 0.0088% | $9.29 | $69,953 | +115.14% | |
| 2025-07-16 | Sale | Goldan Keith A. | Chief Financial Officer | 1,296 0.0015% | $9.29 | $12,033 | +115.14% | |
| 2025-05-19 | Katkin Keith | director | 10,000 0.0114% | $9.11 | $91,120 | +83.33% | ||
| 2025-05-19 | Goldan Keith A. | Chief Financial Officer | 3,000 – | $0 | $0 | +83.33% | ||
| 2025-05-19 | Huber Martin H. Jr. | director | 5,000 0.0056% | $8.99 | $44,950 | +83.33% | ||
| 2025-05-16 | Botwood Nicholas A.J. | Head of R&D, CMO | 11,765 0.0136% | $8.99 | $105,826 | +86.91% |
| Podlesak Dennis | director | 239763 0.2685% | $3.43M | 1 | 5 | +23.96% |
| Goldan Keith A. | Chief Financial Officer | 139252 0.1559% | $1.99M | 2 | 6 | <0.0001% |
| Botwood Nicholas A.J. | Head of R&D, CMO | 60885 0.0682% | $870,046.65 | 1 | 2 | +86.91% |
| ROYSTON IVOR | director | 750545 0.8405% | $10.73M | 1 | 0 | <0.0001% |
| Katkin Keith | director | 100000 0.112% | $1.43M | 1 | 2 | +83.33% |
| Huber Martin H. Jr. | director | 79000 0.0885% | $1.13M | 1 | 0 | +83.33% |
| Morrison Briggs | director | 17836 0.02% | $254,876.44 | 4 | 18 | +43.88% |
| Meyers Michael L. | SVP, Chief Medical Officer | 15666 0.0175% | $223,867.14 | 3 | 0 | +40.96% |
$8,217,280 | 112 | 46.33% | $1.6B | |
$831,902,292 | 108 | 9.34% | $1.2B | |
$54,660,406 | 66 | 22.24% | $1.5B | |
$530,111,731 | 35 | 8.69% | $1.51B | |
$4,431,947 | 22 | 36.10% | $1.46B |
| Increased Positions | 117 | +45.17% | 16M | +15.49% |
| Decreased Positions | 113 | -43.63% | 17M | -16.33% |
| New Positions | 33 | New | 6M | New |
| Sold Out Positions | 29 | Sold Out | 6M | Sold Out |
| Total Postitions | 263 | +1.54% | 100M | -0.83% |
| Blackrock, Inc. | $183,718.00 | 9.91% | 8.63M | -2M | -17.52% | 2025-09-30 |
| Kynam Capital Management, Lp | $181,476.00 | 9.79% | 8.52M | 0 | 0% | 2025-09-30 |
| Goldman Sachs Group Inc | $116,861.00 | 6.31% | 5.49M | -310,761 | -5.36% | 2025-09-30 |
| Vanguard Group Inc | $109,453.00 | 5.91% | 5.14M | +104,683 | +2.08% | 2025-09-30 |
| Point72 Asset Management, L.P. | $90,633.00 | 4.89% | 4.26M | +2M | +100% | 2025-09-30 |
| State Street Corp | $82,081.00 | 4.43% | 3.85M | +410,797 | +11.93% | 2025-09-30 |
| Bank Of America Corp /De/ | $78,762.00 | 4.25% | 3.7M | -141,119 | -3.68% | 2025-09-30 |
| Eversept Partners, Lp | $73,854.00 | 3.99% | 3.47M | -598,041 | -14.71% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $70,545.00 | 3.81% | 3.31M | +2M | +131.21% | 2025-09-30 |
| Kingdon Capital Management, L.L.C. | $53,250.00 | 2.87% | 2.5M | +400,000 | +19.05% | 2025-09-30 |